 Holzer Holzer, LLC is investigating whether DBV Technologies S.A. DBV Technologies or the Company NASDAQ: DBVT complied with federal securities laws. On August 4, 2020, DBV Technologies announced it had received a CRL letter from the FDA outlining concerns regarding the efficacy and corresponding need for further testing of the Companys BLA for Viaskin Peanut. The price of DBV Technologys stock fell following the announcement. 